Why Digital Health Adoption Alone Doesn't Earn Trust
Digital health now spans nearly every part of healthcare and life sciences. It includes digital front doors, electronic health records (EHRs), clinical decision support, connected devices, remote monitoring, AI, and the technologies that support clinical research and product development. Each introduces distinct risks and reshapes how patients, clinicians, institutions, and partners interact with technology and data.
Digital transformation has too often prioritized deploying technology over making it work for the people expected to use it. A patient portal can be available without making care easier to navigate. A clinical tool can perform as intended and still disrupt a clinician’s workflow. A remote monitor can generate accurate data that no one has the capacity or clear responsibility to review. A consent process can meet formal requirements without giving a patient or research participant meaningful understanding or control. In each case, the technology may work while the operating model around it fails.
Digital health creates value only when people have good reason to rely on it. Patients, clinicians, and partners must understand what a tool can do, where its limits lie, who remains accountable, and what happens when it fails. Trust by design embeds those conditions into digital health strategy, workflow design, performance management, and governance from the outset. It is what turns deployed technology into a trusted part of how care is accessed, delivered, and improved.
The Higher the Risk, the Higher the Standard
Digital health tools carry different levels of risk and require different standards of evidence, oversight, and accountability. The appropriate standard depends on what a technology does, the consequences of failure, and the people affected. Online appointment scheduling primarily raises questions about accessibility, identity, and the handling of personal information. Clinical decision support adds evidence quality, bias, explainability, liability, and professional judgment. Remote patient monitoring introduces device accuracy, patient adherence, alert management, and continuity of response. Digitally-enabled clinical research must also address informed consent, endpoint validity, participant burden, and third-party access to data.
Applying the same governance model to every use case can produce controls that are either excessive or insufficient. Requirements designed for high-consequence clinical technologies can subject lower-risk administrative tools to validation, documentation, and approval cycles that delay deployment without reducing risk proportionately. Conversely, governance designed primarily for speed can allow higher-risk technologies to advance without adequate clinical evidence, local validation, bias assessment, human oversight, or post-deployment monitoring.
Digital health governance should therefore scale with the potential harm, sensitivity of the data, degree of automation, vulnerability of the intended population, and reversibility of a poor decision. These factors should determine the evidence required, which decisions remain human, what users need to understand, and how failures will be identified and corrected.
Some healthcare organizations are already translating this principle into practice. Duke Health assigns algorithms considered for patient care to full-review, fast-track, or registration-only pathways through its risk-based algorithm oversight process. The approach demonstrates how organizations can vary the intensity of review while preserving accountability across the technology lifecycle.
Risk calibration must also begin with the need to be addressed and the setting in which the technology will operate. The U.S. Department of Veterans Affairs’ home telehealth model, for example, assesses patients for the suitability of remote monitoring before providing equipment selected for their needs, training, and an assigned care coordinator. The technology operates within a defined care model rather than as a standalone intervention. This approach aligns with the World Health Organization’s emphasis on evidence, interoperability, equitable access, and implementation within health systems.
The appropriate level of assurance must also reflect who bears the risk. Patients need technology that is useful, understandable, and supported by access to human help. Clinicians need reliable evidence, workflow integration, and clear accountability. Regulators require proof of safety, validity, and compliance. Research participants need clarity about burden, monitoring, and secondary data use. Technology and care partners need defined responsibilities across organizational boundaries. Effective governance reconciles these expectations rather than treating trust as a single stakeholder sentiment.
Key Takeaway
Digital health governance should scale with the consequences of failure and the vulnerability of those affected. Each use case requires a defined level of evidence, oversight, transparency, and accountability.
Explore Our Healthcare & Life Sciences Consulting Services
P&C Global’s healthcare and life sciences practice partners with leading health systems and innovators.
Digital Health Adoption Is Not the Same as Trust
Activation, logins, and digital health utilization are attractive measures because they are visible. But they do not explain what prompted use, whether engagement continued, or whether the tool improved care, work, or decision-making.
Patients may use a digital channel because it is fast, required, or the only practical route to care. Clinicians may use a system because it is embedded in the EHR or mandated by the organization. High utilization can therefore coexist with skepticism, workarounds, or poor experience.
Consumer use of AI for health information illustrates this distinction. Nearly one-third of U.S. adults reported using AI for health information or advice, while 77% expressed concern about the privacy of medical information provided to AI tools. Among people who had used AI for health purposes, 41% said they had uploaded personal medical information. These findings relate to consumer AI rather than provider-deployed clinical systems, but they demonstrate that convenience and perceived necessity can prompt use even when confidence in data stewardship remains unsettled.
Adoption can also inherit trust from a human relationship. In 2024, 87% of individuals accessed a patient portal at least once during the year following encouragement of their healthcare provider, compared with 57% of those who received no encouragement. Provider endorsement did more than raise awareness. It showed patients that the portal was part of their care.
This makes value visibility and human reinforcement essential parts of adoption. Patients need to know what a digital service will help them accomplish. Clinicians need evidence that a tool will reduce burden, improve decisions, or strengthen care rather than create an additional layer of work. Organizations also need to distinguish initial use from sustained and appropriate use.
Completion rates, repeat engagement, abandonment, opt-outs, channel switching, workarounds, and requests for human assistance provide a more honest picture than enrollment alone.
Key Takeaway
Use alone does not prove that patients trust the tool or benefit from it. Leaders must understand what drives adoption, whether engagement endures, and whether sustained use improves care, workflows, or decision-making.
Explore Our Healthcare IT Transformation Services
P&C Global’s healthcare IT transformation services embed cyber resilience in connected care delivery.
EHRs Form the Digital Health Trust Infrastructure
Electronic health records (EHRs) are the foundation of digital health. They supply the data used by portals, clinical decision support systems, care-management platforms, remote-monitoring workflows, analytics, and AI. When records are fragmented, difficult to interpret, or disconnected from the point of care, every digital capability built above them inherits those weaknesses.
Patient access has expanded, but the online experience remains fragmented. A recent study found that 59% of individuals reported having multiple online medical records or patient portals, while only 7% used an organizing application to combine information across them. Patient information may be spread across different hospitals, specialists, laboratories, and portals. Patients then have to compare test results, track messages, reconcile care instructions, and piece together information from multiple organizations.
The most recent national ONC analysis found that 71% of U.S. hospitals routinely had necessary external clinical information available electronically at the point of care, but only 42% reported that clinicians often used it when treating patients. Just 43% routinely performed all four measured domains of interoperable exchange: finding, sending, receiving, and integrating information.
The value of integration becomes clearer when digital information supports coordinated action. In a P&C Global engagement with a leading healthcare provider network, connected devices transmitted health data from patients with chronic conditions directly to care teams across multiple hospitals. Clinicians and specialists used real-time information to coordinate treatment adjustments as patient conditions changed. Within the first year, the program reduced hospital readmissions among participating patients by 30%, demonstrating how integrated data, workflows, and clinical accountability can improve outcomes.
The example also shows that interoperability is not only a technical capability. Information must arrive in a form that is timely, relevant, easy to find, and incorporated into the clinical workflow. Data governance must make clear where information originated, whether it is current, who is responsible for it, and how it has been validated. Identity matching, clinical terminology, consent rules, and correction processes must function consistently across systems. Patients need a practical way to flag inaccurate information, and clinicians need to see whether externally sourced data have been reconciled and validated.
Data quality and healthcare interoperability should therefore be treated as trust controls. Before adding an AI layer or a new digital experience, leaders should determine whether the underlying information is sufficiently complete, representative, and usable for the intended purpose. A polished interface cannot compensate for a weak data foundation.
Key Takeaway
EHR quality and interoperability determine the reliability of the broader digital health ecosystem. Trust cannot be designed at the interface while fragmentation and uncertainty persist underneath it.
Clinician Confidence Is Won in the Workflow
Clinicians evaluate digital health tools through experience. They see whether information is accurate, whether alerts are useful, whether the technology fits the sequence of care, and whether someone responds when it fails. Confidence develops through observed performance in real clinical settings, not through enterprise communications or generalized claims about innovation.
A study of 2,067 family physicians found that only 27.2% were very satisfied with their EHR, while approximately one-quarter were somewhat or very dissatisfied. Alignment with clinical workflow, ease of finding relevant information, and usefulness of alerts were associated with greater satisfaction; alerts received the lowest usability ratings among the functions examined.
Physician expectations for healthcare AI reinforce the same point. In the American Medical Association’s 2024 survey, 66% of physicians indicated that they were using AI in their practice. The leading attributes identified as necessary to advance adoption included a designated feedback channel (88%), data privacy assurances (87%), and EHR integration (84%).
Effective implementation begins by redesigning the work, not inserting a tool into the existing process. Leaders must define when the technology appears, what information it uses, who reviews its output, what action is expected, and who remains accountable. They must also decide how clinicians can challenge a recommendation, report a problem, and see whether feedback resulted in a change.
Organizations must confirm that a tool performs safely and reliably in the population, workflow, and data environment where it will be used because performance may not transfer cleanly across settings. A recent multicenter study found that the performance of a widely used sepsis model varied meaningfully across four major U.S. health systems, with area under the receiver operating characteristic curve (AUROC)—a measure of how well a model distinguishes between patients with and without a condition—ranging from 0.82 to 0.92.
Despite moderate to strong discrimination, the model had low positive predictive value and generated a high alert burden. The researchers noted that differences in performance may have reflected the timing and setting of sepsis onset, patient complexity and baseline sepsis rates, as well as variations in clinical workflows, patient volume, and laboratory access that affected how quickly essential data became available. These differences reinforce the need to validate clinical technologies in the specific environments where they will be used.
Transparency must also be useful at the moment of decision. A clinician does not need a technical description of every model component. Instead, the clinician needs the intended use, relevant evidence, data provenance, limitations, confidence, excluded populations, and a clear explanation of how the output should inform care. Human oversight has value only when people have the time, information, authority, and skill to exercise it.
Key Takeaway
Clinician confidence is earned through reliable performance, workflow integration, actionable transparency, and meaningful influence over how a tool evolves. Training cannot rescue technology that makes the work harder or leaves accountability unclear.
Patient Agency Must Extend Beyond Consent
Digital health requires patients and caregivers to place greater trust in how their information and care are managed. They may disclose sensitive information through an app, allow a device to monitor activity continuously, receive test results through a portal, or act on an automated recommendation before speaking with a clinician. A conventional privacy notice or one-time consent form rarely provides enough understanding for these interactions.
Regulation is moving toward a more active model of individual control over health data. The European Health Data Space Regulation (EHDS) entered into force in March 2025 and will apply in phases. Its framework gives individuals greater ability to access and share electronic health data, restrict access, request corrections, and exercise greater control over secondary use. The significance extends beyond European compliance. Digital health systems are increasingly expected to make data practices transparent and individual rights easier to exercise.
Patient agency must be practical, not merely promised. Individuals should understand what information is collected, why it is needed, who can access it, how long it will be retained, and whether it may be used for care, research, product development, or personalization. They also need clarity about what the technology can and cannot do, when a clinician will review information, and where to seek help. Caregivers and legally authorized representatives require access models that support their role while respecting patient preferences.
Personalization requires particular oversight. Leaders should determine whether tailored recommendations and interactions are relevant, proportionate, explainable, and aligned with the individual’s interests. Patients should have meaningful settings and alternatives rather than being forced to choose between unrestricted data sharing and loss of service.
Digital identity and authentication require the same human-centered approach. Strong security protects trust, but overly difficult authentication can exclude patients, increase support burdens, and encourage unsafe workarounds. Effective design balances protection with account recovery, delegated access, and human assistance.
Key Takeaway
Trust requires ongoing understanding, choice, and recourse. Patient agency must remain visible throughout the digital relationship and not end when a box is checked.
Digital Equity Requires Choice, Not Digital-Only Care
Digital health can reduce distance, accelerate access, and make services easier to navigate. It can also reproduce existing disparities when organizations assume that availability creates accessibility. Device ownership and internet access are only the beginning of the divide. Language, disability, health literacy, digital confidence, caregiver support, privacy at home, and the cost of data or equipment can all determine whether a person benefits.
A study of 28,942 patients with cancer across eight U.S. health systems found that 35% had never accessed the patient portal during the study period. Rural residence, limited community broadband access, unemployment, and belonging to racial and ethnic minority groups were associated with lower odds of access. The findings illustrate how digitally enabled care can expand access for some patients while remaining out of reach for others.
Equitable digital health design starts with the needs, circumstances, and barriers of the people the technology is intended to serve, not assumptions about a typical user. It requires testing with people who use assistive technologies, speak different languages, have limited health literacy, share devices, manage complex conditions, or depend on a caregiver. It also requires examining where digital processes transfer work to the patient. Uploading records, troubleshooting a device, interpreting results, and coordinating between portals may appear efficient to the organization while increasing the burden on the individual.
Choice is therefore a design principle. Alternative options should remain available when clinical risk, accessibility needs, or personal circumstances require them. The objective is not to preserve every legacy channel indefinitely. It is to ensure that efficiency is not achieved by excluding the people who find the digital path hardest to use.
Equity must also be measured after launch. Completion, abandonment, response times, escalations, and outcomes should be segmented by population, language, location, disability, device, and channel where legally and ethically appropriate. An overall adoption rate can appear strong while hiding significant and growing differences in use among patient groups.
Key Takeaway
Digital access is equitable only when different populations can complete the same essential tasks and achieve comparable outcomes. Leaders should design for assisted and alternative pathways, then measure who benefits and who is left behind.
Trust Must Extend Across the Life Sciences Ecosystem
For pharmaceutical, biotechnology, and medtech organizations, digital health trust extends beyond care delivery. Digital biomarkers, connected devices, electronic consent, remote data collection, decentralized trial elements, patient support platforms, and real-world evidence create new relationships among participants, investigators, sponsors, technology providers, regulators, and healthcare organizations. Each relationship introduces questions about data integrity, participant burden, access, and accountability.
Digital health technologies used in clinical research must be fit for purpose, validated for the intended setting, usable by the trial population, and supported by appropriate privacy protections and training. Participants should also understand what information will be collected, how it will be used and monitored, who can access it, and how investigators will review and act on the data. FDA guidance on remote data acquisition in clinical investigations reinforces these expectations.
These requirements have strategic implications. A remote technology may reduce travel while increasing the daily burden of charging, wearing, syncing, or troubleshooting a device. A digital measure may collect information continuously while introducing missing data, software-version differences, or changes in behavior caused by monitoring. A third-party platform may extend trial reach while creating uncertainty about data access, licensing terms, or responsibility for participant support.
Sponsors and their partners therefore need a shared operating model for the full technology lifecycle. Contracts should define data rights, security, validation, change control, participant support, incident reporting, performance monitoring, and exit arrangements. Technology updates must be assessed for their effects on measurement and usability. Participants and investigators need a clear support path, while regulators need evidence that the system remained fit for purpose throughout its use.
The same discipline must extend to failure and recovery. An outage, inaccurate measurement, privacy incident, or unexplained change can interrupt research, compromise data integrity, and weaken confidence across the ecosystem. The broader health sector has already demonstrated how quickly third-party disruption can spread. After the 2024 Change Healthcare cyberattack, 74% of nearly 1,000 hospitals surveyed reported direct effects on patient care, while 94% reported financial impact.
Key Takeaway
In digitally enabled research and connected health, trust follows the data across every partner and technology. Accountability must span the full lifecycle rather than stop at the boundary of any one organization.
Measure Trust as an Operating Outcome
Digital health trust is often discussed as though it were a single sentiment. In practice, people may trust a tool’s accuracy but not its data practices, trust the clinician using it but not the company that built it, or appreciate its convenience while doubting that it serves their interests. A single satisfaction or confidence score cannot capture those differences.
A systematic review of trust in digital healthcare found that trust is often poorly defined and inconsistently measured. More than two in five studies did not explain what they meant by trust, while more than one-third relied on measures from non-health settings or tools that had not been adequately validated. The review also found that trust is shaped by data accuracy, privacy, digital literacy, human interaction, user experience, and technology quality.
Organizations need a measurement model that connects the conditions required for trust with the behaviors they influence and the outcomes they produce. The first layer assesses whether the technology is reliable, accessible, understandable, and well governed. The second examines how patients and clinicians respond, including whether they complete key tasks, continue using the tool, opt out, switch channels, or develop workarounds. The final layer measures whether that behavior improves access, safety, clinical performance, experience, cost, and equity. Measuring all three prevents organizations from mistaking strong adoption for trusted use or trusted use for meaningful value.
These measures must be interpreted together. High utilization paired with frequent workarounds may indicate mandated adoption rather than confidence. A low override rate for an AI tool may indicate reliability, but it could also signal automation bias. In a controlled study of AI-assisted MRI diagnosis, AI improved clinicians’ overall accuracy, yet misleading AI recommendations were associated with 45.5% of the errors made during AI-assisted review. High patient satisfaction may also conceal the experiences of people who abandoned the process or never responded to the survey. Direct trust research should therefore use validated questions tailored to the stakeholder, technology, and clinical context.
Executive oversight should focus on the movement from trust conditions to behavior and outcomes. That requires a baseline before implementation, explicit targets, population segmentation, and named accountability for corrective action. Measures should continue after launch because technology, workflows, data, user expectations, and performance all change over time. Trust that is not monitored becomes an assumption.
Key Takeaway
Trust should be measured as a multidimensional operating outcome, not inferred from adoption or satisfaction. The most useful dashboard connects the conditions leaders control with how people behave and the value the technology ultimately delivers.
Trust Is a Digital Health Operating Capability
Digital health does not become trustworthy through messaging added at the end of implementation. Confidence is built through choices made much earlier: which problems deserve a digital health solution, what evidence is sufficient, whose workflow is being changed, what data are required, where human judgment remains essential, and how people will obtain help or challenge an outcome.
Organizations that treat trust as an operating capability will design, govern, and scale digital health differently. They will tier use cases by risk, co-design with the people expected to rely on them, strengthen the EHR and data foundation, make accountability visible, preserve meaningful agency, and monitor performance across the full lifecycle. They will also recognize that the right balance between digital and human interaction depends on the stakes of the decision.
The objective is not universal confidence or frictionless automation. It is digital health that earns reliance by being useful, evidence-based, understandable, inclusive, secure, and accountable. That is how digital transformation earns trust and delivers better care, stronger research, and measurable value.
